Business Context and Reporting Period
Werewolf Therapeutics, Inc. filed this Current Report on Form 8-K on October 28, 2021. The filing concerns a board appointment and related compensatory arrangements; it does not report quarterly or annual financial results.
Key Financial and Corporate Metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics are provided.
- Dr. Meeta Chatterjee will receive annual cash compensation of $35,000 as a director and $4,000 for service on the Nominating and Corporate Governance Committee, plus reasonable expense reimbursement.
- She received an option to purchase 23,200 common shares at an exercise price of $15.97 per share, equal to the closing market price on the appointment date.
Material Changes
- On October 28, 2021, the Board appointed Dr. Chatterjee as a Class II director, serving until the 2023 annual meeting or until her successor is elected and qualified, subject to earlier death, resignation, or removal.
- She was also appointed to the Nominating and Corporate Governance Committee.
- The stock option vests one-third on the first anniversary of the grant date and the remainder in equal monthly installments through the third anniversary, subject to continued board service.
Outlook, Risks, and Unusual Items
- Dr. Chatterjee is Senior Vice President of Global Business Development at Legend Biotech Corporation and previously held business development and licensing roles at Merck Research Laboratories.
- She serves on the board of Editas Medicine, Inc.; the filing does not describe any related-party arrangements or conflicts arising from that role.
- She entered into the Company's standard indemnification agreement for directors.
- The filing provides no financial guidance, forecast, contingency, or new business risk disclosure.
Facts Investors Should Verify
- Confirm the vesting schedule, exercise price, and potential dilution associated with the 23,200-share option.
- Review the Company's non-employee director compensation program and standard indemnification agreement.
- Assess any potential governance or conflict-of-interest considerations related to Dr. Chatterjee's other board and executive positions.
- Consult the Company's subsequent filings for financial results, liquidity, and any additional compensation or governance disclosures.